{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:47:34Z","timestamp":1792784854007,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Anne M.A. Prinsen was sponsored by the Stichting Kwaliteitsgelden Medisch Specialisten","id":[{"id":"https:\/\/ror.org\/02n63hy79","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41391-026-01134-3","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T08:51:01Z","timestamp":1782377461000},"page":"892-899","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A nationwide histopathology study reflecting the impact of the introduction of MRI in the diagnostic trajectory of prostate cancer in routine clinical care"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-6120-3162","authenticated-orcid":false,"given":"Anne M. A.","family":"Prinsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Slagter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo G.","family":"Schoots","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2176-9102","authenticated-orcid":false,"given":"Geert J. L. H.","family":"van Leenders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harm H. E.","family":"van Melick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. P. Michiel","family":"Sedelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5277-6586","authenticated-orcid":false,"given":"Diederik M.","family":"Somford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roderick C. N.","family":"van den Bergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"1134_CR1","unstructured":"ECIS - European Cancer Information System. Long term estimates of cancer incidence and mortality [Internet]. [cited 2022 Oct 25]. Available from: https:\/\/ecis.jrc.ec.europa.eu."},{"key":"1134_CR2","doi-asserted-by":"crossref","unstructured":"Marhold M, Kramer G, Krainer M, Le Magnen C. The prostate cancer landscape in Europe: Current challenges, future opportunities. Cancer Lett. 2022;526:304\u201310.","DOI":"10.1016\/j.canlet.2021.11.033"},{"key":"1134_CR3","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1093\/jnci\/djq099","volume":"102","author":"HG Welch","year":"2010","unstructured":"Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst. 2010;102:605\u201313.","journal-title":"J Natl Cancer Inst"},{"key":"1134_CR4","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.eururo.2013.12.062","volume":"65","author":"S Loeb","year":"2014","unstructured":"Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, et al. Overdiagnosis and Overtreatment of Prostate Cancer. Eur Urol. 2014;65:1046\u201355.","journal-title":"Eur Urol"},{"key":"1134_CR5","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","volume":"378","author":"V Kasivisvanathan","year":"2018","unstructured":"Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med. 2018;378:1767\u201377.","journal-title":"N Engl J Med"},{"key":"1134_CR6","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","volume":"389","author":"HU Ahmed","year":"2017","unstructured":"Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389:815\u201322.","journal-title":"Lancet"},{"key":"1134_CR7","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1910038","volume":"382","author":"M Ahdoot","year":"2020","unstructured":"Ahdoot M, Wilbur A, Reese S, Lebastchi A, Mehralivand S, Gomella P, et al. MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis. N Engl J Med. 2020;382:917\u201328.","journal-title":"N Engl J Med"},{"key":"1134_CR8","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.eururo.2022.03.003","volume":"82","author":"IM Wagensveld","year":"2022","unstructured":"Wagensveld IM, Osses DF, Groenendijk PM, Zijta FM, Busstra MB, Rociu E, et al. A Prospective Multicenter Comparison Study of Risk-adapted Ultrasound-directed and Magnetic Resonance Imaging\u2013directed Diagnostic Pathways for Suspected Prostate Cancer in Biopsy-na\u00efve Men. Eur Urol. 2022;82:318\u201326.","journal-title":"Eur Urol"},{"key":"1134_CR9","unstructured":"Mottet N, Cornford P, van den Bergh RCN, E Briers, M. De Santis, S Gillessen, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer 2022. Arnhem, The Netherlands: EAU Guidelines Office; 2022."},{"key":"1134_CR10","unstructured":"Dutch Society of Urology. Richtlijn Prostaatcarcinoom: Diagnostische prostaat MRI. 2019. Accessed June 21, 2026. https:\/\/richtlijnendatabase.nl\/richtlijn\/prostaatcarcinoom\/diagnostiek\/beeldvormend_onderzoek\/diagnostische_prostaat_mri_bij_prostaatcarcinoom.html"},{"key":"1134_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2025.02.007","author":"SB Nalavenkata","year":"2025","unstructured":"Nalavenkata SB, Vertosick E, Briganti A, Ahmed H, Eldred-Evans D, Gordon S, et al. Variation in Prostate Magnetic Resonance Imaging Performance: Data from the Prostate Biopsy Collaborative Group. Eur Urol Oncol. 2025. https:\/\/doi.org\/10.1016\/j.euo.2025.02.007.","journal-title":"Eur Urol Oncol"},{"key":"1134_CR12","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s00345-019-02899-0","volume":"38","author":"IG Schoots","year":"2020","unstructured":"Schoots IG, Padhani AR. Personalizing prostate cancer diagnosis with multivariate risk prediction tools: how should prostate MRI be incorporated? World J Urol. 2020;38:531\u201345.","journal-title":"World J Urol"},{"key":"1134_CR13","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.eururo.2019.05.029","volume":"76","author":"M Van Der Leest","year":"2019","unstructured":"Van Der Leest M, Isra\u00ebl B, Cornel EB, Z\u00e1mecnik P, Schoots IG, Van Der Lelij H, et al. High Diagnostic Performance of Short Magnetic Resonance Imaging Protocols for Prostate Cancer Detection in Biopsy-na\u00efve Men: The Next Step in Magnetic Resonance Imaging Accessibility. Eur Urol. 2019;76:574\u201381.","journal-title":"Eur Urol"},{"key":"1134_CR14","first-page":"14","volume":"28","author":"Bestuur NNvR","year":"2023","unstructured":"NNvR Bestuur. Grenzen aan de zorg!. MemoRad. 2023;28:14\u20137.","journal-title":"MemoRad"},{"key":"1134_CR15","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/bju.14515","volume":"123","author":"PH Shah","year":"2019","unstructured":"Shah PH, Patel VR, Moreira DM, George AK, Alom M, Kozel Z, et al. Implementation of multiparametric magnetic resonance imaging technology for evaluation of patients with suspicion for prostate cancer in the clinical practice setting. BJU Int. 2019;123:239\u201345.","journal-title":"BJU Int"},{"key":"1134_CR16","doi-asserted-by":"publisher","unstructured":"Siddiqui MR, Ansbro B, Shah PV, Aguiar JA, Li EV, Rich JM, et al. Real-world use of MRI for risk stratification prior to prostate biopsy. Prostate Cancer Prostatic Dis. 2022. https:\/\/doi.org\/10.1038\/s41391-022-00543-4.","DOI":"10.1038\/s41391-022-00543-4"},{"key":"1134_CR17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1155\/2007\/971816","volume":"29","author":"M Casparie","year":"2007","unstructured":"Casparie M, Tiebosch ATMG, Burger G, Blauwgeers H, Van De Pol A, Van Krieken JHJM, et al. Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol. 2007;29:19\u201324. https:\/\/doi.org\/10.1155\/2007\/971816.","journal-title":"Cell Oncol"},{"key":"1134_CR18","doi-asserted-by":"publisher","unstructured":"Schoots I, Haider M, Punwani S, Padhani A MRI in Prostate Cancer Screening: A Review and Recommendations, From the AJR Special Series on Screening. AJR. 2025;16. https:\/\/doi.org\/10.2214\/AJR.24.32588.","DOI":"10.2214\/AJR.24.32588"},{"key":"1134_CR19","doi-asserted-by":"publisher","unstructured":"Schoots IG, Ahmed HU, Albers P, Asbach P, van den Bergh RCN, Godtman RA, et al. Magnetic Resonance Imaging\u2013based Biopsy Strategies in Prostate Cancer Screening: A Systematic Review. Eur Urol. 2025. https:\/\/doi.org\/10.1016\/j.eururo.2025.05.038.","DOI":"10.1016\/j.eururo.2025.05.038"},{"key":"1134_CR20","unstructured":"Centraal Bureau voor de Statistiek (CBS). CBS Dataportaal - 85496NED [Internet]. 2024 [cited 2025 Aug 29]. Available from: https:\/\/opendata.cbs.nl\/statline\/portal.html?_la=nl&_catalog=CBS&tableId=85496NED&_theme=62."},{"key":"1134_CR21","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.eururo.2018.11.023","volume":"75","author":"M van der Leest","year":"2019","unstructured":"van der Leest M, Cornel E, Isra\u00ebl B, Hendriks R, Padhani AR, Hoogenboom M, et al. Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-na\u00efve Men with Elevated Prostate-specific Antigen: A Large Prospective Mu. Eur Urol. 2019;75:570\u20138.","journal-title":"Eur Urol"},{"key":"1134_CR22","doi-asserted-by":"publisher","first-page":"59.e1","DOI":"10.1016\/j.urolonc.2021.07.027","volume":"40","author":"A Yu","year":"2022","unstructured":"Yu A, Yamany T, Mojtahed A, Hanna N, Nicaise E, Harisinghani M, et al. Combination MRI-targeted and systematic prostate biopsy may overestimate gleason grade on final surgical pathology and impact risk stratification. Urol Oncol: Semin Original Investig. 2022;40:59.e1\u201359.e5.","journal-title":"Urol Oncol: Semin Original Investig"},{"key":"1134_CR23","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s00345-019-02848-x","volume":"38","author":"G Ploussard","year":"2020","unstructured":"Ploussard G, Beauval JB, Lesourd M, Almeras C, Assoun J, Aziza R, et al. Performance of systematic, MRI-targeted biopsies alone or in combination for the prediction of unfavourable disease in MRI-positive low-risk prostate cancer patients eligible for active surveillance. World J Urol. 2020;38:663\u201371.","journal-title":"World J Urol"},{"key":"1134_CR24","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.euros.2024.08.017","volume":"70","author":"KRV Straat","year":"2024","unstructured":"Straat KRV, Hagens MJ, Cools Paulino Pereira LJ, van den Bergh RCN, Mazel JW, Noordzij MA, et al. Risk Calculator Strategy Before Magnetic Resonance Imaging Stratification for Biopsy-na\u00efve Men with Suspicion for Prostate Cancer: A Cost-effectiveness Analysis. Eur Urol Open Sci. 2024;70:52\u20137.","journal-title":"Eur Urol Open Sci"},{"key":"1134_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00345-024-04780-1","volume":"42","author":"P Krausewitz","year":"2024","unstructured":"Krausewitz P, Borkowetz A, Ortner G, Kornienko K, Wenzel M, Westhoff N. Do we need MRI in all biopsy na\u00efve patients? A multicenter cohort analysis. World J Urol. 2024;42:1\u20137.","journal-title":"World J Urol"},{"key":"1134_CR26","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1001\/jama.2025.3579","volume":"333","author":"A Kinnaird","year":"2025","unstructured":"Kinnaird A, Luger F, Cash H, Ghai S, Urdaneta-Salegui LF, Pavlovich CP, et al. Microultrasonography-Guided vs MRI-Guided Biopsy for Prostate Cancer Diagnosis: The OPTIMUM Randomized Clinical Trial. JAMA. 2025;333:1679\u201387.","journal-title":"JAMA"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01134-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01134-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01134-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:00:18Z","timestamp":1790719218000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01134-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1134"],"URL":"https:\/\/doi.org\/10.1038\/s41391-026-01134-3","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"9 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"COMPETING INTERESTS","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The study protocol was approved by the local Medical Research Ethics Committee (Medical Research Ethics Committees United, registration number W22.225). The requirement for informed consent was waived. All procedures were performed in accordance with the ethical standards of the institutional and national research committees and with the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}